Filtered By:
Specialty: Drugs & Pharmacology
Drug: Coumadin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 300 results found since Jan 2013.
Predicting treatment effects of a new-to-market drug in clinical practice based on phase III randomized trial results
Clin Pharmacol Ther. 2023 Jun 26. doi: 10.1002/cpt.2983. Online ahead of print.ABSTRACTTrial results may not be generalizable to target populations treated in clinical practice with different distributions of baseline characteristics that modify the treatment effect. We used outcome models developed with trial data to predict treatment effects in Medicare populations. We used data from the Randomized Evaluation of Long-Term Anticoagulation Therapy trial (RE-LY), which investigated the effect of dabigatran vs. warfarin on stroke or systemic embolism (stroke/SE) among patients with atrial fibrillation. We developed outcome m...
Source: Clinical Pharmacology and Therapeutics - June 27, 2023 Category: Drugs & Pharmacology Authors: HoJin Shin Shirley V Wang Dae Hyun Kim Ethan Alt Mufaddal Mahesri Lily G Bessette Sebastian Schneeweiss Mehdi Najafzadeh Source Type: research
Direct Oral Anticoagulation versus Warfarin in Left Ventricular Thrombus: Pooled Analysis of Randomized Controlled Trials
In conclusion, pooled analysis of RCT data favors DOAC over VKA in patients with LV thrombus both in terms of efficacy and safety. This article is protected by copyright. All rights reserved.PMID:37139934 | DOI:10.1002/jcph.2267
Source: The Journal of Clinical Pharmacology - May 4, 2023 Category: Drugs & Pharmacology Authors: Anders Olof Sahl én Haowen Jiang Yee How Lau Lucky Cuenza F Aaysha Cader Mohammed Al-Omary Purich Surunchupakorn Ka Hei Ho Jonathan Sung Derek Lee Satoshi Honda Ack Tan Wei Chieh Jonathan Yap Source Type: research
Dabigatran Dosing Proposal for Adults with Atrial Fibrillation: Stress-testing Renal Function Range in Real World Patients
Clin Pharmacol Ther. 2023 Apr 7. doi: 10.1002/cpt.2902. Online ahead of print.ABSTRACTDabigatran is the first of four direct-acting oral anticoagulants approved to prevent stroke in adult patients with atrial fibrillation using a fixed 2-dose scheme compared to warfarin dosing adjusted to a prothrombin time range associated with optimal risk reduction in stroke and serious bleeding. The pivotal phase 3 trial found dabigatran, depending on dose, is superior to warfarin in stroke reduction and similar in bleeding risk while also showing dabigatran efficacy and safety correlate with steady-state plasma concentrations. Since t...
Source: Clinical Pharmacology and Therapeutics - April 7, 2023 Category: Drugs & Pharmacology Authors: J Robert Powell Farah Al Qaraghuli Jill Fiedler-Kelly Daniel Gonzalez Daniel Weiner Source Type: research
Drug-drug interactions with direct oral anticoagulants for the prevention of ischemic stroke and embolism in atrial fibrillation: a narrative review of adverse events
Expert Rev Clin Pharmacol. 2023 Mar 2. doi: 10.1080/17512433.2023.2187376. Online ahead of print.ABSTRACTINTRODUCTION: In randomized trials, direct oral anticoagulants (DOAC) were non-inferior to the vitamin-K-antagonist (VKA) warfarin in preventing stroke/embolism in patients with atrial fibrillation (AF). DOAC are substrates for P-glycoprotein (P-gp), CYP3A4 and CYP2C9. The activity of these enzymes is modulated by several drugs which might induce pharmacokinetic drug-drug interactions (DDI). Drugs affecting platelet function have the potential for pharmacodynamic DDI of DOAC.AREAS COVERED: The literature was searched fo...
Source: Pharmacological Reviews - March 2, 2023 Category: Drugs & Pharmacology Authors: Claudia St öllberger Birke Schneider Josef Finsterer Source Type: research
